EYPT FY 2025 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M-27.5% YoY

Gross Profit

$29M93.4% margin

Operating Income

-$243M-776.0% margin

Net Income

-$232M-739.4% margin

EPS (Diluted)

$-3.17

Cash Flow

Operating Cash Flow

-$240M

Free Cash Flow

-$243M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$364M

Total Liabilities

$58M

Stockholders' Equity

$306M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$43M	-27.5%
Gross Profit	$29M	$40M	-25.9%
Operating Income	-$243M	-$146M	-66.9%
Net Income	-$232M	-$131M	-77.2%